Tariq Ali Ahmad, MD
Interventional Cardiology · Wilkes Barre, PANPI 1437472941
Payments from drug & device makers
Across 162 payments — averaging $363.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$37K
- Abbott$20K
- Edwards Lifesciences$745
- Inari Medical, Inc.$343
- Shockwave Medical, Inc$228
- W. L. Gore & Associates, Inc.$146
- plus $639 from 12 others
What the payments were for
- Speaking & faculty fees$3,9947%
- Grants$45,50077%
- Travel & lodging$3,4416%
- Food & beverage$5,90610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 83 | $36,710 |
| Abbott | 21 | $20,031 |
| Edwards Lifesciences | 10 | $745 |
| Inari Medical, Inc. | 6 | $343 |
| Shockwave Medical, Inc | 6 | $228 |
| W. L. Gore & Associates, Inc. | 2 | $146 |
| Novartis | 6 | $99 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $90 |
| AstraZeneca | 7 | $88 |
| Boston Scientific | 4 | $69 |
| Penumbra, Inc. | 1 | $67 |
| Boehringer Ingelheim | 3 | $66 |
| Teleflex LLC | 2 | $55 |
| Cardiovascular Systems Inc. | 2 | $29 |
| Terumo Medical Corporation | 1 | $25 |
| Johnson & Johnson | 1 | $20 |
| Angiodynamics, Inc. | 1 | $17 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$58,841 in reported general payments places this provider in the 75th percentile of 281 interventional cardiology providers in Pennsylvania.
See all interventional cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metoprolol Succinate | 38 | $518 |
| Torsemide | 18 | $375 |
| ClopidogrelClopidogrel Bisulfate | 15 | $352 |
| Atorvastatin Calcium | 32 | $350 |
| Lisinopril | 22 | $249 |
| Rosuvastatin Calcium | 17 | $183 |
| Furosemide | 21 | $126 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Wilkes Barre
- William GrayWynnewood$3.3M
- Eric GnallWynnewood$2.4M
- Howard HerrmannPhiladelphia$2.2M
- Ramzi KhalilPittsburgh$1.6M
- Nishant SethiScranton$1.3M
- Matthew BeckerErie$1.3M
- David LasordaPittsburgh$1.1M
- Nainesh PatelAllentown$1.1M
- Jay GiriPhiladelphia$1M
- James HarveyChambersburg$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.